Trial Profile

XIENCE V Everolimus Eluting Coronary Stent System (EECSS) China: Post-Approval Randomized Control Trial (RCT)

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 08 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Everolimus (Primary) ; Sirolimus
Indications Coronary artery disease; Coronary artery restenosis
Focus Therapeutic Use
Sponsors Abbott Vascular

Most Recent Events

04 Nov 2014 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.
09 Jun 2014 Planned End Date changed from 1 Feb 2014 to 1 Jun 2014 as reported by ClinicalTrials.gov record.
07 Oct 2013 Planned end date changed from 1 Oct 2013 to 1 Feb 2014 as reported by ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com